ES2534305T3 - Método para aislamiento de polipéptidos solubles - Google Patents
Método para aislamiento de polipéptidos solubles Download PDFInfo
- Publication number
- ES2534305T3 ES2534305T3 ES10190155.1T ES10190155T ES2534305T3 ES 2534305 T3 ES2534305 T3 ES 2534305T3 ES 10190155 T ES10190155 T ES 10190155T ES 2534305 T3 ES2534305 T3 ES 2534305T3
- Authority
- ES
- Spain
- Prior art keywords
- vhs
- isolation
- protein
- soluble polypeptides
- trypsin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920001184 polypeptide Polymers 0.000 title description 2
- 102000004196 processed proteins & peptides Human genes 0.000 title description 2
- 108090000765 processed proteins & peptides Proteins 0.000 title description 2
- 238000002955 isolation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 10
- 102000004142 Trypsin Human genes 0.000 description 7
- 108090000631 Trypsin Proteins 0.000 description 7
- 239000012588 trypsin Substances 0.000 description 7
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 3
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 3
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004900 laundering Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000001469 pulsed-field gradient nuclear magnetic spectroscopy Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Communicable Diseases (AREA)
Abstract
Un fragmento de anticuerpo que comprende la secuencia de SEQ ID NO: 22.
Description
5
10
15
20
25
30
35
40
45
50
55
60
E10190155
31-03-2015
HVHP414 con una mutación c-Myc N132E y con un residuo metionina adicional en el término N. En resumen, los datos de PFG-NMR (no presentados) indicaban que todas las muestras de proteína tenían los pesos moleculares monómeros esperados incluso a las concentraciones de proteína relativamente altas utilizadas para los experimentos NMR.
Se investigó ulteriormente la estabilidad de los VHs en términos de su resistencia a tripsina en cuanto a integridad a 37ºC después de incubaciones largas a 37ºC. La tripsina escinde las cadenas principales amídicas de los polipéptidos en el término C de un residuo Arg o Lys. Existen 9-13 residuos Arg y Lys en los VHs humanos (Figura2). Existe también un residuo Lys adicional en la etiqueta c-Myc del terminal C que es sensible a la digestión por tripsina. La Figura 4a es un análisis SDS-PAGE de HVHP414 durante la digestión con tripsina. En el transcurso de una hora, la banda original se convertía completamente en un producto simple que tenía una movilidad esperada para el VH sin etiqueta c-Myc-His5 alguna. Se obtuvo el mismo resultado para otros 12 VHs después de incubación de una hora con tripsina. La espectrometría de masas sobre una muestra seleccionada al azar de los VHs tratados con tripsina (a saber, HVHP414, HVHP419, HVHP420, HVHP423, HVHP429, HVHP430 y HVHM81) confirmó que en todos los casos la masa molecular del producto digerido correspondía a un VH con el c-Myc Lys como el residuo Cterminal. HVHM41 daba un fragmento significativamente más corto que el resto después de digestión, y en este caso los experimentos de espectrometría de masas mapeaban el sitio de escisión en la Arg 99 en CDR3 (datos no presentados).
Once VHs comprendidos en concentración desde 0,32 mg/ml (HVHP428) hasta 3,2 mg/ml (HVHP420) se incubaron a 37ºC durante 17 días. Su estabilidad se determinó subsiguientemente en términos de estado de oligomerización y fijación de proteína A. Como se demostró por cromatografía de permeación en gel, el tratamiento de VHs a 37ºC no inducía formación alguna de agregados: todos los VHs daban perfiles de cromatograma que eran virtualmente idénticos a los de VHs sin tratar y se mantenían esencialmente como monómeros (véase el ejemplo para HVHP420; Figura 4c). Para asegurarse de que los VHs mantenían su plegamiento nativo después de tratamiento a 37ºC, se seleccionaron al azar dos VHs, a saber, HVHP414 (1,2 mg/ml) y HVHP420 (3,2 mg/ml), y se determinaron sus KDs de fijación a proteína A por SPR (datos presentados para HVHP420; recuadro en la Figura 4c) y se compararon con los KDs obtenidos para VHs sin tratar (Tabla 2). Los KDs calculados para los VHs tratados térmicamente eran 1,4 μM y 1,0 μM para HVHP414 y HVHP420, respectivamente. Estos valores son esencialmente idénticos a los valores correspondientes para los VHs sin tratar (Tabla 2), demostrando que el tratamiento de VHs a 37ºC no afectaba a su plegamiento nativo. La posibilidad de que los VHs puedan haber estado en un plegamiento no nativo menos compacto durante los periodos de incubación a 37ºC y hayan adquirido nuevamente su plegamiento original después de volver a la temperatura ambiente durante los experimentos de filtración en gel y SPR es poco probable, a la vista del hecho de que los VHs eran resistentes a tripsina a 37ºC (véase arriba), una propiedad asociada típicamente para proteínas nativas bien plegadas.
La eficiencia de replegado (RE) de los VHs humanos se investigó por comparación de los valores KDs de la fijación de los VHs nativos (KDn) y los replegados y tratados térmicamente (KDref) a la proteína A (Tanha, J. et al., 2002). Cuando se desactiva una fracción del VH por tratamiento térmico, el valor KD medido debe ser mayor, dado que este parámetro está basado en la concentración de fragmento de anticuerpo plegado, es decir, activo. Así, la ratio de KDn a KDref da una medida de la RE de VH. La Figura 5 compara sensogramas para fijación de HVHP423 a proteína A inmovilizada en estados nativo (líneas gruesas) y replegado (líneas delgadas) para varias concentraciones de VH seleccionadas. Como puede verse, la fijación del VH replegado a proteína A es menor en todos los casos, lo que indica que el desplegado no es totalmente reversible. Para cada uno de los 14 VHs, se midió la fijación a la proteína A en ambos estados nativo y replegado a varias concentraciones, y se determinaron los valores KDs y subsiguientemente REs (Tabla 2, no se muestran los valores KDref). Se determinaron también los valores KDs y REs de dos VHHs anti-idiotípicos de llama, H11F9 y H11B2, que se utilizaron como referencias. Cuatro VHs tenían REs en el intervalo de 92%-95%, similares a las REs para H11F9 y H11B2, 95% y 100%, respectivamente. Otros cinco tenían REs en el intervalo de 84%-88% y tres superiores a 70%. Únicamente dos tenían RE significativamente menor: HVHP413 (52%) y HVHP421 (14%). Varios VHHs publicados examinados con anterioridad tenían RE próxima a 50% (van der Linden, R.H. et al., 1999).
Construcción y lavado en batea de bibliotecas de presentación de fago VH humanas. Se sintetizó cDNA a partir de mRNA de bazo humano (Ambion Inc., Austin, TX) utilizando iniciadores hexanucleotídicos aleatorios y el kit de DNA de la Primera Cadena™ (GE Healthcare, Baie d'Urfé, QC, Canadá). Utilizando los cDNAs como molde, genes de VH con secuencias CH flanqueantes se amplificaron por la reacción en cadena de polimerasa (PCR) en nueve reacciones separadas utilizando iniciadores específicos de la región de entramado 1 (FR1) de VH y un iniciador específico de inmunoglobina M (de Haard, H.J. et al., 1999). Los productos se purificaron en gel y se utilizaron como el molde en la segunda tanda de PCR para construir genes de VH utilizando los iniciadores específicos FR1 y FR4 (de Haard, H.J. et al., 1999) que introducían también sitios de restricción flanqueantes Apa lI y Not I para propósitos de clonación. Los DNAs del repertorio VH resultantes se clonaron en el vector de fago fd-tetGIIID y se construyó una biblioteca de presentación de fago de VH (Tanha, J. et al., 2001). El lavado en batea contra proteína A (Amersham Biosciences Inc.) se realizó como se ha descrito (Tanha, J. et al., 2001). La asignación de secuencias de la línea germinal de los VHs seleccionados se realizó utilizando el software DNAPLOT, Version 2.0.1 y V BASE Version 1.0. (http://vbase.dnaplot.de/cqi-bin/vbase/vsearch.pl). Se aislaron los VHHs de llama H11C7, H11F9 y H11B2 de una biblioteca de presentación de fago VHH de llama por lavado en batea contra H11 scFv como se ha
10
Claims (1)
-
imagen1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66495405P | 2005-03-25 | 2005-03-25 | |
US664954P | 2005-03-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2534305T3 true ES2534305T3 (es) | 2015-04-21 |
Family
ID=37023360
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10190093.4T Active ES2565782T3 (es) | 2005-03-25 | 2006-03-24 | Método para aislamiento de polipéptidos solubles |
ES10190225.2T Active ES2546788T3 (es) | 2005-03-25 | 2006-03-24 | Método para aislamiento de polipéptidos solubles |
ES10190248.4T Active ES2536995T3 (es) | 2005-03-25 | 2006-03-24 | Método para aislamiento de polipéptidos solubles |
ES10190143.7T Active ES2558338T3 (es) | 2005-03-25 | 2006-03-24 | Método para aislamiento de polipéptidos solubles |
ES06721715T Active ES2375826T3 (es) | 2005-03-25 | 2006-03-24 | Método para aislamiento de polipéptidos solubles. |
ES10190242.7T Active ES2531537T3 (es) | 2005-03-25 | 2006-03-24 | Método para aislamiento de polipéptidos solubles |
ES10190187.4T Active ES2550836T3 (es) | 2005-03-25 | 2006-03-24 | Método para aislamiento de polipéptidos solubles |
ES10190155.1T Active ES2534305T3 (es) | 2005-03-25 | 2006-03-24 | Método para aislamiento de polipéptidos solubles |
Family Applications Before (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10190093.4T Active ES2565782T3 (es) | 2005-03-25 | 2006-03-24 | Método para aislamiento de polipéptidos solubles |
ES10190225.2T Active ES2546788T3 (es) | 2005-03-25 | 2006-03-24 | Método para aislamiento de polipéptidos solubles |
ES10190248.4T Active ES2536995T3 (es) | 2005-03-25 | 2006-03-24 | Método para aislamiento de polipéptidos solubles |
ES10190143.7T Active ES2558338T3 (es) | 2005-03-25 | 2006-03-24 | Método para aislamiento de polipéptidos solubles |
ES06721715T Active ES2375826T3 (es) | 2005-03-25 | 2006-03-24 | Método para aislamiento de polipéptidos solubles. |
ES10190242.7T Active ES2531537T3 (es) | 2005-03-25 | 2006-03-24 | Método para aislamiento de polipéptidos solubles |
ES10190187.4T Active ES2550836T3 (es) | 2005-03-25 | 2006-03-24 | Método para aislamiento de polipéptidos solubles |
Country Status (10)
Country | Link |
---|---|
US (5) | US8293233B2 (es) |
EP (46) | EP2351841A1 (es) |
JP (7) | JP5171611B2 (es) |
AT (1) | ATE531800T1 (es) |
AU (1) | AU2006227536B9 (es) |
CA (8) | CA2868865A1 (es) |
ES (8) | ES2565782T3 (es) |
PL (1) | PL2360255T3 (es) |
PT (1) | PT2360255E (es) |
WO (1) | WO2006099747A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2444133A1 (en) | 2001-04-16 | 2002-10-24 | Wyeth Holdings Corporation | Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
AU2005333603A1 (en) | 2004-10-21 | 2007-01-04 | Wyeth | Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens |
EP2351841A1 (en) * | 2005-03-25 | 2011-08-03 | National Research Council of Canada | Method for isolation of soluble polypeptides |
CN102838673B (zh) | 2007-06-25 | 2016-05-11 | 艾斯巴技术-诺华有限责任公司 | 修饰抗体的方法和具有改善的功能性质的修饰抗体 |
WO2009089295A2 (en) * | 2008-01-07 | 2009-07-16 | Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Anti-hiv domain antibodies and method of making and using same |
WO2010060216A1 (en) * | 2008-11-26 | 2010-06-03 | National Research Council Of Canada | Nanoaggregate embedded beads conjugated to single domain antibodies |
CA2815888C (en) * | 2010-10-25 | 2020-06-30 | National Research Council Of Canada | Clostridium difficile-specific antibodies and uses thereof |
ES2746559T3 (es) | 2011-01-28 | 2020-03-06 | Nat Res Council Canada | Modificación genética de dominios de inmunoglobulina |
WO2014043509A2 (en) * | 2012-09-13 | 2014-03-20 | Novartis Ag | Antigen binding molecule with terminal modifications |
JP6591964B2 (ja) | 2013-04-23 | 2019-10-16 | ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン | Icoslへの治療上の標的特異的vnarドメインの単離 |
US10184008B2 (en) | 2014-12-19 | 2019-01-22 | Medimmune Limited | Blood brain barrier transport molecules and uses thereof |
ES2852001T3 (es) | 2015-01-23 | 2021-09-10 | Helix Biopharma Corp | Conjugados de anticuerpo-ureasa para propósitos terapéuticos |
PL3370768T3 (pl) | 2015-11-03 | 2022-06-13 | Janssen Biotech, Inc. | Przeciwciała specyficznie wiążące pd-1 i ich zastosowania |
KR20200128703A (ko) * | 2018-03-06 | 2020-11-16 | 프레시전 인코포레이티드 | B형 간염 백신 및 이의 용도 |
EP3762022A4 (en) * | 2018-03-06 | 2022-06-15 | Precigen, Inc. | VACCINES AGAINST HUMAN PAPILLOMAVIRUS AND USES THEREOF |
WO2020041360A1 (en) | 2018-08-21 | 2020-02-27 | Quidel Corporation | Dbpa antibodies and uses thereof |
US20210188971A1 (en) | 2019-12-19 | 2021-06-24 | Quidel Corporation | Monoclonal antibody fusions |
AR124914A1 (es) * | 2021-02-18 | 2023-05-17 | Mitsubishi Tanabe Pharma Corp | Nuevo anticuerpo anti-pad4 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
CA2090126C (en) * | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
US5766886A (en) | 1991-12-13 | 1998-06-16 | Xoma Corporation | Modified antibody variable domains |
US5965408A (en) * | 1996-07-09 | 1999-10-12 | Diversa Corporation | Method of DNA reassembly by interrupting synthesis |
US6596850B1 (en) | 1998-01-30 | 2003-07-22 | Ixsys, Incorporated | Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same |
US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
DK1171468T3 (da) * | 1999-04-09 | 2008-10-20 | Univ Zuerich | Fremgangsmåde til stabilisering af kimære immunoglobuliner eller immunoglobulinfragmenter, samt stabiliseret anti-EGP-2-scFv-fragment |
GB9911569D0 (en) * | 1999-05-18 | 1999-07-21 | Oxford Biomedica Ltd | Antibodies |
EP1242457B1 (en) * | 1999-12-28 | 2004-08-11 | Esbatech AG | Intrabodies with defined framework that is stable in a reducing environment and applications thereof |
EP1268555A2 (en) * | 2000-03-27 | 2003-01-02 | The Regents of The University of California | Ligands directed to the non-secretory component, non-stalk region of pigr and methods of use thereof |
JP2004512010A (ja) | 2000-03-29 | 2004-04-22 | ディージーアイ・バイオテクノロジーズ・エル・エル・シー | インスリン及びigf−1受容体のアゴニスト及びアンタゴニスト |
EP1156060B1 (en) * | 2000-05-12 | 2007-06-27 | GPC Biotech AG | Human peptides/proteins causing or leading to the killing of cells including lymphoid tumor cells |
PT2281843T (pt) * | 2000-06-16 | 2017-01-02 | Human Genome Sciences Inc | Anticorpos que se ligam imunoespecificamente a blys |
JP3375941B2 (ja) * | 2000-11-24 | 2003-02-10 | 科学技術振興事業団 | 高効率抗体スクリーニング法 |
WO2002051870A2 (en) * | 2000-12-22 | 2002-07-04 | GRAD, Carole Legal Representative of KAPLAN, Howard | Phage display libraries of human vh fragments |
WO2002059340A1 (en) * | 2001-01-26 | 2002-08-01 | The Scripps Research Institute | Immunopolypeptides to hepatitis c virus |
DE10123041A1 (de) * | 2001-05-11 | 2002-11-28 | Tobias Heintges | Humane hochaffine Antikörperfragmente gegen essentielle Proteine von Hepatitis-C-Virus |
JP2004538324A (ja) * | 2001-08-03 | 2004-12-24 | メディカル リサーチ カウンシル | 細胞内抗体 |
JP4190005B2 (ja) * | 2001-08-22 | 2008-12-03 | 株式会社抗体研究所 | 結合性分子の選択方法 |
GB0124317D0 (en) * | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
AU2003205125A1 (en) | 2002-01-14 | 2003-07-30 | George W. Gokel | Synthetic ion channels |
WO2003070752A2 (en) * | 2002-02-20 | 2003-08-28 | Dyax Corporation | Mhc-peptide complex binding ligands |
GB0226727D0 (en) * | 2002-11-15 | 2002-12-24 | Medical Res Council | Intrabodies |
DK2332989T3 (en) | 2002-05-22 | 2015-05-11 | Esbatech Alcon Biomed Res Unit | IMMUNGLOBULIN FRAMEWORKS PROVIDING IMPROVED STABILITY IN THE INTRACELLULAR ENVIRONMENT AND PROCEDURES FOR IDENTIFICATION THEREOF |
WO2003102136A2 (en) * | 2002-05-30 | 2003-12-11 | Human Genome Sciences, Inc. | Antibodies that specifically bind to neurokinin b |
AU2003239197A1 (en) | 2002-06-07 | 2003-12-22 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of | Novel stable anti-cd22 antibodies |
EP2366718A3 (en) * | 2002-06-28 | 2012-05-02 | Domantis Limited | Ligand |
EP1539236A4 (en) * | 2002-07-03 | 2007-07-18 | Univ Pennsylvania | COMPOSITIONS, METHODS AND KITS RELATING TO ANTIPLATELET AUTOANTIBODIES AND THEIR INHIBITORS |
JP2006521088A (ja) | 2002-11-15 | 2006-09-21 | メディカル リサーチ カウンシル | 抗活性化ras抗体 |
NZ542306A (en) * | 2003-03-14 | 2008-04-30 | Wyeth Corp | Antibodies against human IL-21 receptor and uses therefor |
CA2524737A1 (en) * | 2003-05-06 | 2005-02-24 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
AR045614A1 (es) | 2003-09-10 | 2005-11-02 | Hoffmann La Roche | Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos |
TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
CA2560889A1 (en) * | 2004-03-23 | 2005-10-13 | Sanjay D. Khare | Monoclonal antibodies specific for human ox40l (cd 134l) |
CN104804095A (zh) * | 2004-08-05 | 2015-07-29 | 健泰科生物技术公司 | 人源化抗c-met 拮抗剂 |
EP1789451A4 (en) | 2004-08-12 | 2009-12-02 | Dyax Corp | TIE COMPLEX BINDING PROTEINS |
EP2351841A1 (en) * | 2005-03-25 | 2011-08-03 | National Research Council of Canada | Method for isolation of soluble polypeptides |
WO2010060216A1 (en) * | 2008-11-26 | 2010-06-03 | National Research Council Of Canada | Nanoaggregate embedded beads conjugated to single domain antibodies |
ES2746559T3 (es) * | 2011-01-28 | 2020-03-06 | Nat Res Council Canada | Modificación genética de dominios de inmunoglobulina |
WO2014043509A2 (en) * | 2012-09-13 | 2014-03-20 | Novartis Ag | Antigen binding molecule with terminal modifications |
-
2006
- 2006-03-24 EP EP10190176A patent/EP2351841A1/en not_active Withdrawn
- 2006-03-24 EP EP10190187.4A patent/EP2322624B1/en not_active Not-in-force
- 2006-03-24 CA CA2868865A patent/CA2868865A1/en not_active Abandoned
- 2006-03-24 EP EP10190100A patent/EP2368992A3/en not_active Withdrawn
- 2006-03-24 CA CA2873899A patent/CA2873899C/en active Active
- 2006-03-24 EP EP10190145A patent/EP2368994A3/en not_active Withdrawn
- 2006-03-24 EP EP10190194A patent/EP2322621A3/en not_active Withdrawn
- 2006-03-24 AU AU2006227536A patent/AU2006227536B9/en not_active Ceased
- 2006-03-24 ES ES10190093.4T patent/ES2565782T3/es active Active
- 2006-03-24 EP EP10190215A patent/EP2330195A3/en not_active Withdrawn
- 2006-03-24 EP EP10190232A patent/EP2316945A1/en not_active Withdrawn
- 2006-03-24 EP EP10190177A patent/EP2339000A1/en not_active Withdrawn
- 2006-03-24 ES ES10190225.2T patent/ES2546788T3/es active Active
- 2006-03-24 EP EP10190158A patent/EP2339001A2/en not_active Withdrawn
- 2006-03-24 EP EP10190247A patent/EP2330196A3/en not_active Withdrawn
- 2006-03-24 EP EP10190143.7A patent/EP2374886B1/en active Active
- 2006-03-24 EP EP10190236A patent/EP2336327A1/en not_active Withdrawn
- 2006-03-24 PL PL10190155T patent/PL2360255T3/pl unknown
- 2006-03-24 CA CA2868774A patent/CA2868774A1/en not_active Abandoned
- 2006-03-24 EP EP10190102A patent/EP2368993A3/en not_active Withdrawn
- 2006-03-24 ES ES10190248.4T patent/ES2536995T3/es active Active
- 2006-03-24 EP EP10190173A patent/EP2371960A3/en not_active Withdrawn
- 2006-03-24 EP EP10190104A patent/EP2336323A3/en not_active Withdrawn
- 2006-03-24 EP EP10190249A patent/EP2338998A1/en not_active Withdrawn
- 2006-03-24 EP EP10190155.1A patent/EP2360255B1/en not_active Not-in-force
- 2006-03-24 EP EP10190237A patent/EP2336328A1/en not_active Withdrawn
- 2006-03-24 EP EP06721715A patent/EP1869182B1/en not_active Not-in-force
- 2006-03-24 EP EP10190165A patent/EP2336325A1/en not_active Withdrawn
- 2006-03-24 EP EP10190242.7A patent/EP2360256B1/en active Active
- 2006-03-24 EP EP10190248.4A patent/EP2333066B1/en not_active Not-in-force
- 2006-03-24 EP EP10190246A patent/EP2333067A1/en not_active Withdrawn
- 2006-03-24 JP JP2008502207A patent/JP5171611B2/ja not_active Expired - Fee Related
- 2006-03-24 EP EP10190225.2A patent/EP2377935B1/en active Active
- 2006-03-24 EP EP10190147A patent/EP2368995A3/en not_active Withdrawn
- 2006-03-24 EP EP10190169A patent/EP2336326A3/en not_active Withdrawn
- 2006-03-24 EP EP10190160A patent/EP2316947A1/en not_active Withdrawn
- 2006-03-24 EP EP10190180A patent/EP2345723A1/en not_active Withdrawn
- 2006-03-24 EP EP10190201A patent/EP2374887A3/en not_active Withdrawn
- 2006-03-24 CA CA2868867A patent/CA2868867A1/en not_active Abandoned
- 2006-03-24 EP EP10190082A patent/EP2316946A1/en not_active Withdrawn
- 2006-03-24 CA CA2602028A patent/CA2602028C/en not_active Expired - Fee Related
- 2006-03-24 EP EP10190091A patent/EP2338999A3/en not_active Withdrawn
- 2006-03-24 EP EP10190162A patent/EP2322623A3/en not_active Withdrawn
- 2006-03-24 EP EP10190240A patent/EP2377936A3/en not_active Withdrawn
- 2006-03-24 PT PT101901551T patent/PT2360255E/pt unknown
- 2006-03-24 AT AT06721715T patent/ATE531800T1/de active
- 2006-03-24 ES ES10190143.7T patent/ES2558338T3/es active Active
- 2006-03-24 EP EP10190205A patent/EP2338997A1/en not_active Withdrawn
- 2006-03-24 EP EP10190086A patent/EP2368990A1/en not_active Withdrawn
- 2006-03-24 EP EP10190150A patent/EP2336324A2/en not_active Withdrawn
- 2006-03-24 EP EP10190235A patent/EP2371961A1/en not_active Withdrawn
- 2006-03-24 EP EP10190089A patent/EP2333068A1/en not_active Withdrawn
- 2006-03-24 CA CA2873939A patent/CA2873939C/en active Active
- 2006-03-24 EP EP10190210A patent/EP2351842A1/en not_active Withdrawn
- 2006-03-24 WO PCT/CA2006/000451 patent/WO2006099747A1/en active Application Filing
- 2006-03-24 CA CA2873906A patent/CA2873906C/en active Active
- 2006-03-24 EP EP10190153A patent/EP2322622A3/en not_active Withdrawn
- 2006-03-24 EP EP10190093.4A patent/EP2368991B1/en not_active Not-in-force
- 2006-03-24 ES ES06721715T patent/ES2375826T3/es active Active
- 2006-03-24 EP EP10190233A patent/EP2368996A3/en not_active Withdrawn
- 2006-03-24 EP EP10190149A patent/EP2363485A1/en not_active Withdrawn
- 2006-03-24 CA CA2868781A patent/CA2868781A1/en not_active Abandoned
- 2006-03-24 ES ES10190242.7T patent/ES2531537T3/es active Active
- 2006-03-24 ES ES10190187.4T patent/ES2550836T3/es active Active
- 2006-03-24 EP EP10190244A patent/EP2368997A3/en not_active Withdrawn
- 2006-03-24 EP EP10190206A patent/EP2386638A3/en not_active Withdrawn
- 2006-03-24 EP EP10190222A patent/EP2316948A1/en not_active Withdrawn
- 2006-03-24 US US11/887,113 patent/US8293233B2/en not_active Expired - Fee Related
- 2006-03-24 ES ES10190155.1T patent/ES2534305T3/es active Active
-
2011
- 2011-11-22 JP JP2011254988A patent/JP5731956B2/ja not_active Expired - Fee Related
-
2012
- 2012-10-19 US US13/656,099 patent/US20130142780A1/en not_active Abandoned
-
2014
- 2014-03-28 JP JP2014070227A patent/JP5901679B2/ja not_active Expired - Fee Related
-
2015
- 2015-09-11 US US14/851,641 patent/US10150807B2/en active Active
- 2015-10-22 JP JP2015208267A patent/JP6374851B2/ja active Active
- 2015-10-22 JP JP2015208269A patent/JP2016073284A/ja active Pending
-
2018
- 2018-02-06 JP JP2018018992A patent/JP6628822B2/ja active Active
- 2018-12-05 US US16/210,621 patent/US11091536B2/en active Active
-
2019
- 2019-07-03 JP JP2019124468A patent/JP6878508B2/ja active Active
-
2021
- 2021-07-12 US US17/372,966 patent/US11993643B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2534305T3 (es) | Método para aislamiento de polipéptidos solubles | |
Koide et al. | The importance of being tyrosine: lessons in molecular recognition from minimalist synthetic binding proteins | |
US8791238B2 (en) | Artificial binding proteins based on ubiquitin | |
ES2536509T3 (es) | OB-fold usado como estructura para diseño por ingeniería de nuevos agentes de unión específicos | |
Hackel et al. | Stability and CDR composition biases enrich binder functionality landscapes | |
Liu et al. | Isolation of anti-toxin single domain antibodies from a semi-synthetic spiny dogfish shark display library | |
ES2881683T3 (es) | Procedimiento para mejorar las características de las proteínas | |
US8592179B2 (en) | Artificial binding proteins based on a modified alpha helical region of ubiquitin | |
CN105924519B (zh) | 全面单克隆抗体产生 | |
JP2004502451A (ja) | 人工抗体ポリペプチド | |
ES2873375T3 (es) | Métodos de cribado de anticuerpos | |
Mandrup et al. | A novel heavy domain antibody library with functionally optimized complementarity determining regions | |
BR112012027863A2 (pt) | composições, métodos e usos de domínio de fibronectina estabilizada. | |
Sharma et al. | Subtle changes at the variable domain interface of the T-cell receptor can strongly increase affinity | |
Visintin et al. | Intracellular antibodies for proteomics | |
Rentero et al. | Screening of large molecule diversities by phage display | |
Lopez et al. | Identification of highly selective MMP‐14 inhibitory Fabs by deep sequencing | |
CA2708074A1 (en) | Non-aggregating human vh domains | |
Moreira et al. | Epitope mapping by phage display | |
Chambers | High-throughput antibody production | |
O’Brien et al. | Evaluating the conformation and binding interface of cap-binding proteins and complexes via ultraviolet photodissociation mass spectrometry | |
US20160003843A1 (en) | Engineered antibody scaffolds | |
Garcia-Calvo et al. | Development of a new recombinant antibody, selected by phage-display technology from a celiac patient library, for detection of gluten in foods | |
Zhao et al. | Selection of bisphenol A–single-chain antibodies from a non-immunized mouse library by ribosome display | |
Lim et al. | Development and structural characterisation of human scFv targeting MDM2 spliced variant MDM215kDa |